Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

Executive Summary

FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.

You may also be interested in...



Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch

Intercept announced that the US FDA has set April 22 as date for an advisory committee review of OCA in NASH, meaning March 26 action date could be pushed back as much as three months.

Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On

Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy. 

US FDA References Off-Label Use In Otherwise Bland Labeling Draft Guidance

Product labels can be required to have warnings related to commonly prescribed unapproved uses with significant safety risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel